BIVI
Companies
NASDAQ
BioVie Inc.
Health Care
$1.09
-$0.91 (-45.50%)
Price Chart
Overview
About BIVI
BioVie Inc is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
Market Cap
$26.3M
Volume
549.6K
Avg. Volume
687.8K
P/E Ratio
-0.23582767
Dividend Yield
0.00%
Employees
13.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.85
Moderate Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
High Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, BIVI shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$26.3M
Volume549.6K
P/E Ratio-0.24
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
February 13, 2024Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025